CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 20,000 shares at an average $213.67 ($4,273,311)
- 4 Open-market sale CBO & COO sold 25,000 shares at an average $215.20 ($5,379,940)
- 4 Open-market sale General Counsel and Secretary sold 27,500 shares at an average $204.94 ($5,635,944)
- 8-K Event Other events
- 424B5 Offering Prospectus
- 4 Shares withheld for taxes CBO & COO gave up 9,392 shares (to pay taxes)
- 4 Option exercise Chief Executive Officer acquired 13,800 shares (option exercise)
- 4 Open-market sale Executive VP, Head of R&D sold 23,551 shares at an average $149.23 ($3,514,610)
- 4 Open-market sale Director sold 15,000 shares at an average $148.95 ($2,234,266)
- 4/A Open-market sale Director sold 33,000 shares at an average $143.35 ($4,730,448)
- 8-K Event Other events
- 4 Open-market sale Director sold 33,000 shares at an average $143.35 ($4,730,448)
- 4 Open-market sale Chief Executive Officer sold 20,000 shares at an average $142.29 ($2,845,782)
- 8-K Event Other events
Page 22 of 45 · 883 filings